Drug-induced gynecomastia

Expert Opinion on Drug Safety

Volumn 7, Issue 6, 2008, Pages 691-702

  Eckman, Ari ^a   Dobs, Adrian ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast; Drug induced; Gynecomastia; Hypogonadism

Indexed keywords

ANTIANDROGEN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; ANTIULCER AGENT; AROMATASE INHIBITOR; BICALUTAMIDE; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CARDIAC AGENT; CIMETIDINE; DIETHYLSTILBESTROL; DIGITALIS GLYCOSIDE; ESTROGEN; FLUTAMIDE; HISTAMINE H2 RECEPTOR ANTAGONIST; HYPOCHOLESTEROLEMIC AGENT; KETOCONAZOLE; METHOTREXATE; NEUROLEPTIC AGENT; NILUTAMIDE; NUCLEOSIDE ANALOG; PLACEBO; PROTEINASE INHIBITOR; PROTON PUMP INHIBITOR; SPIRONOLACTONE; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMOXIFEN; TESTOSTERONE; UNINDEXED DRUG;

BONE MARROW DISEASE; BREAST TENDERNESS; CLINICAL TRIAL; COCCIDIOIDOMYCOSIS; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUODENUM ULCER; GYNECOMASTIA; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERPROLACTINEMIA; HYPERTENSION; HYPOGONADISM; LIVER DISEASE; LUNG DISEASE; MALE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL ASSESSMENT; MENTAL DISEASE; MONOTHERAPY; ORAL MUCOSAL DISEASE; PATHOGENESIS; PATHOPHYSIOLOGY; PREVALENCE; PROSTATE CANCER; PROSTATE HYPERTROPHY; PSORIASIS; REVIEW; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; ANDROGEN ANTAGONISTS; ANIMALS; AROMATASE INHIBITORS; CHILD; ESTROGENS; GYNECOMASTIA; HUMANS; HYPERPROLACTINEMIA; HYPOGONADISM; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PHARMACEUTICAL PREPARATIONS; TAMOXIFEN; YOUNG ADULT;

EID: 57049090142     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330802442382     Document Type: Review

References (118)

1. Braunstein GD. Pubertal gynecomastia. In: Lifshitz F, editor, Pediatric endocrinology. Marcel Dekker, New York; 1996. p. 197
2. Braunstein GD. Diagnosis and treatment of gynecomastia. Hosp Pract (Off Ed) 1993;28:37
3. Moore MP. Male breast cancer. In: Harris JR, Lippman ME, Morrow M, Hellman S, editors, Diseases of the breast. Lippincott-Raven, Philadelphia; 1996. p. 859
4. Schmidt-Voigt J. Brustdruenschwellungen bei mannlichen Jugendlichen des Pubertatsalters (Pubertatsmakromastie). Z Kindefheilkd 1941;62:590
5. Braunstein GD. Gynecomastia. N Engl J Med 1993;328(7):490-5
6. Nydick M, Bustos J, Dale JH Jr, Rawson RW. Gynecomastia in adolescent boys. JAMA 1961;178:449
7. Lee PA. The relationship of concentrations of serum hormones to pubertal gynecomastia. J Pediatr 1975;86:212
8. Fara GM, DelCorvo G, Bernuzzi S, et al. Epidemic of breast enlargement in an Italian school. Lancet 1979;2:295
9. Harlan WR, Grillo GP, Cornoni-Huntley J, Leaverton PE. Secondary sex characteristics of boys 12 to 17 years of age: The US Health Examination Survey. J Pediatr 1979;95:293
10. Moore DC, Schlaepfer LV, Paunier L, Sizonenko PC. Hormonal changes during puberty: v. transient pubertal gynecomastia: abnormal androgen-estrogen ratios. J Clin Endocrinol Metab 1984;58:492
11. Biro FM, Lucky AW, Huster GA, Morrison JA. Hormonal studies and physical maturation in adolescent gynecomastia. J Pediatr 1990;116:450
12. Williams MJ. Gynecomastia. Its incidence, recognition and host characterization in 447 autopsy cases. Am J Med 1963;34:103
13. Nuttall FQ. Gynecomastia as a physical finding in normal men. J Clin Endocrinol Metab 1979;48:338
14. Carlson HE. Gynecomastia. N Engl J Med 1980;303:795
15. Niewoehner CB, Nuttall FQ. Gynecomastia in a hospitalized male population. Am J Med 1984;77:633
16. Murray NP, Daly MJ. Gynaecomastia and heart failure Adverse drug reaction or disease process? J Clin Pharm Ther 1991;16:275
17. Georgiadis E, Papandreou L, Evangelopoulou C, et al. Incidence of gynaecomastia in 954 young males and its relationship to somatometric parameters. Ann Hum Biol 1994;21:579
18. Pirke KM, Doerr P. Age related changes and interrelationships between plasma testosterone, oestradiol and testosterone-binding globulin in normal adult males. Acta Endocrinol 1973;74:792
19. Stearns EL, MacDonnell JA, Kaufman BJ, et al. Declining testicular function with age: hormonal and clinical correlates. Am J Med 1974;57:761
20. Harmon SM, Tsitouras PD. Reproductive hormones in aging men. I. Measurement of sex steroids, basal luteinizing hormone, and Leydig cell response to human chorionic gonadotropin. J Clin Endocrinol Metab 1980;51:35
21. Large DM, Anderson DC. Twenty-four hour profiles of circulating androgens and estrogens in male puberty with and without gynecomastia. Clin Endocrinol 1979;11:505
22. Moore DC, Schlaepfer LV, Paunier L, Sizonenko PC. Hormonal changes during puberty. V. Transient pubertal gynecomastia: abnormal androgen-estrogen ratios. J Clin Endocrinol Metab 1984;58:492
23. Biro F, Lucky A, Huster G, et al. Hormonal studies and physical maturation in adolescent gynecomastia. J Pediatr 1990;116:450
24. Villalpando S, Mondragon L, Barron C, et al. Role of testosterone and dihydrotestosterone in spontaneous gynecomastia of adolescents. Arch Androl 1992;28:171
25. Glass AR. Gynecomastia. In: Becker K, editor, Principles and practice of endocrinology and metabolism. Lippincott, Williams, and Wilkins, Philadelphia; 2nd edition textbook 1995;1123-9
26. Coen P, Kulin H, Ballantine T, et al. An aromatase-producing sex-cord tumor resulting in prepubertal gynecomastia. N Engl J Med 1991;324:317
27. Saver MA, Rifka SM, Hawke RL, et al. Marijuana: interaction with the estrogen receptor. J Pharmacol Exp Ther 1983;224:404
28. Chen AC, Petrylak DP. Complications of androgen deprivation therapy in men with prostate cancer. Curr Oncol Rep 2004;6:209-15
29. Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology 2003;61(2 suppl 1):32-8
30. Holzbeierlein JM. Managing complications of androgen deprivation therapy for prostate cancer. Urol Clin North Am 2006;33:181-90
31. Harle LK, Maggio M, Shahani S, et al. Endocrine complications of androgen-deprivation therapy in men with prostate cancer. Clin Adv Hematol Oncol 2006;4:687-96
32. Thompson CA, Shanafelt TD, Loprinzi CL. Andropause: symptom management for prostate cancer patients treated with hormonal ablation. Oncologist 2003;8:474-87
33. Chen AC, Petrylak DP. Complications of androgen deprivation therapy in men with prostate cancer. Curr Oncol Rep 2004;6:209-15
34. McLeod DG, Iversen P. Gynecomastia in patients with prostate cancer: a review of treatment options. Urology 2000;56:713-20
35. See WA, Wirth MP, McLeod DG, et al. Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol 2002;168:429-35
36. Peyriere H, Mauboussin JM, Rouanet I, et al. Report of gynecomastia in five male patients during antiretroviral therapy for HIV infection. AIDS 1999;13:2167-91
37. Donovan B, Bodsworth NJ, Mulhall B, Allen D. Gynecomastia associated with saquinavir therapy. Int J STD AIDS 1999;10:49-50
38. Piroth L, Grappin M, Petit JM, et al. incidence of gynecomastia in men infected with HIV and treated with highly active antiretroviral therapy. Scand J Infect Dis 2001;33:559-560
39. Mercie P, Viallard JF, Rodolphe T, et al. Efavirenz-associated breast hypertrophy in HIV-infected patients. AIDS 2001;15:126-8
40. Caso JA, Prieto JM, Casas E, Sanz J. Gynecomastia without lipodystrophy syndrome in HIV-infected men treated with efavirenz. AIDS 2001;15:1447-52
41. Qazi NA, Morlese JF, King DM, et al. Gynecomastia without lipodystrophy in HIV-1 seropositive patients on efavirenz: an alternative hypothesis. AIDS 2002;16:506-7
42. Jover F, Cuadrado JM, Roig P, et al. Efavirenz-associated gynecomastia: report of five cases and review of the literature. Breast J 2004;10(3):244-6
43. Evans DL, Pantanowitz L, Dezube BJ, Aboulafia DM. Breast enlargement in 13 men who were seropositive for human immunodeficiency virus. Clin Infect Dis 2002;35:1113-9
44. Qazi NA, Morlese JF, King DM, et al. True gynaecomastia, another manifestation of immune reconstitution disease?. Int J STD AIDS 2002;13:59-65
45. Funder JW, Mercer JE. Cimetidine, a histamine H2 receptor antagonist, occupies androgen receptors. J Clin Endocrinol Metab 1979;48:189
46. Garcia Rodrigueaz LA, Jick H. Risk of gynecomastia associated with cimetidine, omeprazole, and other antiulcer drugs. BMJ 1994;308:503
47. Spence RW, Clestin LR. Gynecomastia associated with cimetidine. Gut 1979;20:154-7
48. Jensen RT, Collen MJ, Pandol SJ, et al. Cimetidine-induced impotence and breast changes in patients with gastric hypersecretory states. N Engl J Med 1983;308(15):883-7
49. Santucci L, Farroni F, Fiorucci S, et al. Gynaecomastia during omeprazole therapy. N Engl J Med 1991;324:635
50. Convens C, Verhelst J, Mahler C. Painful gynaecomastia during omeprazole therapy. Lancet 1991;338:1153
51. Carvajal A, Martin Arias LH. Gynaecomastia and sexual disorders after the administration of omeprazole. Am J Gastroenterol 1995;90(6):1028-9
52. Lindquist M, Edwards IR. Endocrine adverse effects of omeprazole. BMJ 1992;305:451-2
53. Adverse Drug Reactions Advisory Committee. Drug-induced gynaecomastia. Aust Adverse Drug React Bull 1997;16:3
54. Carvajal A, Macias D, Gutierrez A, et al. Gynaecomastia associated with proton pump inhibitors a case series from the Spanish pharmacovigilance system. Drug Saf 2007;30(6):527-31
55. Satoh T, Munakata H, Fujita K, et al. Studies on the interactions between drug and estrogen. II. On the inhibitory effect of 29 drugs reported to induced gynaecomastia on the oxidation of estradiol at C-2 or C-17. Biol Pharm Bull 2003;26:695-700
56. Maestri E, Camellini L, Rossi G, et al. Effects of five days verapamil administration on serum GH and PRL levels. Horm Metab Res 1985;17:482
57. Turkington RW. Serum prolactin levels in patients with gynecomastia. J Clin Endocrinol Metab 1972;34:62-6
58. Franks S, Jacobs HS, Martin N, Nabarro JD. Hyperprolactinaemia and impotence. Clin Endocrinol 1978;8(4):277-87
59. Tanner LA, Bosco LA. Gynecomastia associated with calcium channel blocker therapy. Arch Intern Med 1988;148:379-80
60. Cornes PGS, Hole AC. Amlodipine gynecomastia. Breast 2001;10:544-5
61. Zochling J, Large G, Fassett R. Gynaecomastia and amlodipine. Med J Aust 1994;160(12):807
62. Markusse HM, Meyboom RH. Gynecomastia associated with captopril. BMJ 1988;296:1262
63. Kahl LE, Medsger TA, Klein I. Massive breast enlargement in a patient receiving D-penicillamine for systemic sclerosis. J Rheumatol 1985;12(5):990-1
64. Reid DM, Martynoga AG, Nuki G. Reversible gynaecomastia associated with D-penicillamine in a man with rheumatoid arthritis. BMJ (Clin Res Ed) 1982;285(6348):1083-4
65. Gardette V, et al. Gynecomastia associated with fenofibrate. Ann Pharmacother 2007;41(3):508-10
66. Novartis Pharmaceuticals Corporation. Lescol (fluvastatin) package insert. East Hanover, NJ; 2003
67. Merck & Co., Inc. Zocor (simvastatin) package insert. Whitehouse Station, NJ; 2004
68. Merck & Co., Inc. Mevacor (lovastatin) package insert. Whitehouse Station, NJ; 2005
69. Burckhardt C, Vera CA, LaDue JS. Effect of digitalis on urinary pituitary gonadotropin excretion. Ann Intern Med 1968;68:1069-71
70. Stoffer SS, Hynes KM, Jiang N-S, Ryan RJ. Digoxin and abnormal serum hormone levels. JAMA 1973;225:1643-4
71. Rose LI, Underwood RH, Newmark SR, et al. Pathophysiology of spironolactone-induced gynecomastia. Ann Intern Med 1977;87(4):398-403
72. Huffman DH, Kampmann JP, Hignite CE, Azarnoff DL. Gynecomastia induced in normal males by spironolactone. Clin Pharmacol Ther 1978;24:465-73
73. Caminos-Torres R, Ma L, Snyder PJ. Gynecomastia and semen abnormalities induced by spironolactone in normal men. J Clin Endocrinol Metab 1977;45:255-60
74. Shalet SM. Disorders of the endocrine system due to radiation and cytotoxic chemotherapy. Clin Endocrinol 1983;18:637
75. Trump DL, Pary MD, Staal S. Gynecomastia in men following antineoplastic therapy. Arch Intern Med 1982;142:511
76. Lee SC, Ellis RJ. Mate breast cancer during finasteride therapy. J Natl Cancer Inst 2004;96(4):338-9
77. Green L, Wysowski DK, Fourcroy JL. Gynecomastia and breast cancer during finasteride therapy. N Engl J Med 1996;335:823
78. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-24
79. Roehrborn C, Marks L, Fenter T, et al. Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. Urology 2004;63(4):709-15
80. Kaneda Y, Fujii A, Yamaoks T, et al. Neither gynaecomastia nor galactorrhea is a common side effect of neuroleptics in male patients. Neuroendocrinol Lett 2000;21:447-51
81. Hummer M, Kemmler G, Kurz M, et al. Sexual disturbances during clozapine and haloperidol treatment for schizophrenia. Am J Psychiatry 1999;156:631-3
82. Hamner MB, Arana GW. Hyperprolactinemia in antipsychotic-treated patients: guidelines for avoidance and management. CNS Drugs 1998;10:209-22
83. Citrome L, Volavka J. The promise of atypical antipsychotics. Fewer side effects mean enhanced compliance and improved functioning. Postgrad Med 2004;116:49-51
84. Meltzer HY, Busch DA, Fang VS. Serum neuroleptic and prolactin levels in schizophrenic patients and clinical response. Psychiatry Res 1983;9:271-83
85. De Leon J, Diaz FJ, Josiassen RC, et al. Possible individual and gender differences in the small increases in plasma prolactin levels seen during clozapine treatment. Eur Arch Psychiatry Clin Neurosci 2004;254:318-25
86. Byerly M, Suppes T, Tran QV, Baker RA. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 2007;276:639-61
87. Karagianis JL, Baksh A. High-dose olanzapine and prolactin levels. J Clin Psychiatry 2004;64:1192-4
88. Kelly DL, Conley RR. A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Psychoneuroendocrinology 2006;31:340-6
89. Tandon R, Halbreich U. The second-generation 'atypical' antipsychotics: similar improved efficacy but different neuroendocrine side effects. Psychoneuroendocrinology 2003;28(1):1-7
90. Molitch ME. Medication-induced hyperprolactinemia. Mayo Clin Proc 2005;80:1050-7
91. Goff DC, Posever T, Herz L, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol 1998;18:296-304
92. Potkin SG, Saha AR, Kujawa MJ, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-90
93. Kane J, Canas F, Kramer M, et al. Treatment of schizophrenia with paliperidone extended-release tablets: a 6-week placebo-controlled trial. Schizophr Res 2007;90:147-61
94. Pont A, Williams PL, Azhar S, et al. Ketoconazole blocks testosterone synthesis. Arch Intern Med 1982;142:2137
95. Sugar AM, Alsip SG, Galgiani JN, et al. Pharmacology and toxicity of high-dose ketoconazole. Antimicrob Agents Chemother 1987;31(12):1874-8
96. Aguire MA, et al. Gynecomastia and sexual impotence associated with methotrexate treatment. J Rheumatol 2002;29:1793-4
97. Pandhi D, et al. Gynecomastia with oligospermia: an unusual complication of low-dose methotrexate for pustular psoriasis. Clin Exp Dermatol 2005;31:138-40
98. Glass AR, et al. Gynecomastia after chemotherapy for lymphoma. Arch Intern Med 1979;139:1048-9
99. Braunstein GD. Gynecomastia. N Engl J Med 1993;328:490-5
100. Rosner W, Auchus RJ, Azziz R, et al. Utility, limitations, and pitfalls in measuring testosterone: an Endocrine Society position statement. J Clin Endocrinol Metab 2007;92:405-13
101. Rohrich RJ, Ha RY, Kenkel JM, Adams WP Jr. Classification and management of gynecomastia: defining the role of ultrasound-assisted liposuction. Plast Reconstr Surg 2003;111:909-23
102. Tashkandi M, Al-Qattan MM, Hassanain JM, et al. The surgical management of high-grade gynecomastia. Ann Plast Surg 2004;53:17-20
103. Treves N. Gynecomastia; the origins of mammary swelling in the male: an analysis of 406 patients with breast hypertrophy, 525 with testicular tumors, and 13 with adrenal neoplasms. Cancer 1958;11:1083-102
104. Gruntmanis U, Braunstein GD. Treatment of gynecomastia. Curr Opin Investig Drugs 2001;2:643-9
105. Eversmann T, Moito J, Von Werder K. Testosterone and estradiol levels in male gynecomastia: clinical and endocrine findings during treatment with tamoxifen. Dtsch Med Wochenschr 1984;109:1678-82
106. Parker LN, Gray DR, Lai MK, Levin ER. Treatment of gynecomastia with tamoxifen: a double-blind crossover study. Metabolism 1986;35:705-8
107. Alagaratnam TT. Idiopadiic gynecomastia treated with tamoxifen: a preliminary report. Clin Ther 1987;9:483-4
108. Konig R, Schonberger W, Neumann P, et al. Treatment of marked gynecomastia in puberty with tamoxifen. Klin Padiatr 1987;199:389-91
109. Dermott MT, Hofeldt FD, Kidd GS. Tamoxifen therapy for painful idiopathic gynecomastia. South Med J 1990;83:1283-5
110. Staiman VR, Lowe FC. Tamoxifen for flutamide/finasteride-induccd gynecomastia. Urology 1997;50:929-33
111. Ting ACW, Chow LWC, Leung YF. Comparison of tamoxifen with danazol in the management of idiopathic gynecomastia. Am Surg 2000;66:38-40
112. Khan HN, Rampaul R, Blamey RW. Management of physiological gynaecomastia with tamoxifen. Breast 2004;13:61-5
113. Lawrence SE, Faught KA, Vethamuthu J, Lawson ML. Beneficial effects of raloxifene and tamoxifen in the treatment of pubertal gynecomastia. J Pediatr 2004;145:71-6
114. Hanavadi S, Banerjee D, Monypenny IJ, Mansel RE. The role of tamoxifen in the management of gynaecomastia. Breast 2006;15:276-80
115. Plourde PV, Reiter EO, Jou HC, et al. Safety and efficacy of anastrozole for the treatment of pubertal gynecomastia: a randomized, double-blind, placebo-controlled trial. J Clin Endocrinol Metab 2004;89:4428-33
116. Boccardo F, Rubagotti A, Battaglia M, et al. Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer. J Clin Oncol 2005;23:808-15
117. Saltzstein D, Sieber P, Morris T, Gallo J. Prevention and management of bicalutamide-induced gynecomastia and breast pain: randomized endocrinologic and clinical studies with tamoxifen and anastrozole. Prostate Cancer Prostatic Dis 2005;8:75-83
118. Perdonà S, Autorino R, De Placido S, et al. Efficacy of tamoxifen and radiotherapy for prevention and treatment of gynaecomastia and breast pain caused by bicalutamide in prostate cancer: a randomised controlled trial. Lancet Oncol 2005;6:295-300